PubMed Health⌕ Search

PubMed · 16634596

Equatorially connected diruthenium(II,III) units toward paramagnetic supramolecular structures with singular magnetic properties.

Abstract

The reaction of Ru2Cl(O2CMe)(DPhF)3 (DPhF = N,N'-diphenylformamidinate) with mono- and polycarboxylic acids gives a clean substitution of the acetate ligand, leading to the formation of complexes Ru2Cl(O2CC6H5)(DPhF)3 (1), Ru2Cl(O2CC6H4-p-CN)(DPhF)3 (2), [Ru2Cl(DPhF)3(H2O)]2(O2C)2 (3), [Ru2Cl(DPhF)3]2[C6H4-p-(CO2)2] (4), and [Ru2Cl(DPhF)3]3[C6H3-1,3,5-(CO2)3] (5). The preparation of [Ru2(NCS)(DPhF)3]3[C6H3-1,3,5-(CO2)3] (6) and {[Ru2(DPhF)3(H2O)]3[C6H3-1,3,5-(CO2)3]}(SO3CF3)3 (7) from 5 is also described. All complexes are characterized by elemental analysis, IR and electronic spectroscopy, mass spectrometry, cyclic voltammetry, and variable-temperature magnetic measurements. The crystal structure determinations of complexes 2.0.5THF and 3.THF.4H2O (THF = tetrahydrofuran) are reported. The reactions carried out demonstrate the high chemical stability of the fragment [Ru2(DPhF)3]2+, which is preserved in all tested experimental conditions. The stability of this fragment is also corroborated by the mass spectra. Electrochemical measurements reveal in all complexes one redox process due to the equilibrium Ru2(5+) <--> Ru2(6+). In the polynuclear complex 7, some additional oxidation processes are also observed that have been ascribed to the presence of two types of dimetallic units rather than two consecutive reversible oxidations. The magnetic behavior toward temperature for complexes 1-7 from 300 to 2 K is analyzed. Complexes 1-7 show low values of antiferromagnetic coupling in accordance with the molecular nature in 1 and 2 and the absence of important antiferromagnetic interaction through the carboxylate bridging ligands in 3-7, respectively. In addition, the magnetic properties of complex 7 do not correspond to any magnetic behavior described for diruthenium(II,III) complexes. The experimental data of compound 7 are simulated considering a physical mixture of S = 1/2 and 3/2 spin states. This magnetic study demonstrates the high sensitivity of the electronic configuration of the unit [Ru2(DPhF)3]2+ to small changes in the nature of the axial ligands. Finally, the energy gap between the pi and delta orbitals in these types of compounds allows the tentative assignment of the transition pi --> delta.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Carmen Barral, Teresa Gallo, Santiago Herrero, Reyes Jiménez-Aparicio, M Rosario Torres, Francisco A Urbanos. 2006-05-01. Equatorially connected diruthenium(II,III) units toward paramagnetic supramolecular structures with singular magnetic properties.. https://doi.org/10.1021/ic052174t

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗